Morgan Stanley Starts Agomab Therapeutics (AGMB) at Overweight

Morgan Stanley analyst Judah Frommer initiates coverage on Agomab Therapeutics (NASDAQ: AGMB) with a Overweight rating and a price target of $28.00.

The analyst comments: "AgomAb is developing ontunisertib (AGMB-129) and AGMB-447 for fibrotic conditions. Both candidates are small molecule inhibitors of ALK5, a well-known target involved in TGF-ß signaling that has been implicated in a number of fibrotic conditions. Historical drug development efforts to inhibit TGF-ß have largely failed due to systemic (e.g., cardiac) toxicities. Both ontunisertib (in Ph2a for FSCD) and AGMB-447 (in Ph1b for IPF) have been designed to overcome this hurdle by acting locally in the tissues of interest (the gut and lungs, respectively), which has translated to encouraging safety profiles in early clinical trials. While data are early for both programs, we see risk/reward as skewed to the upside heading into 2026 based on (i) the strong mechanistic rationale for targeting TGF-ß in fibrotic conditions, (ii) the potential blockbuster opportunities in FSCD and IPF, and (iii) encouraging clinical data that point to target engagement with improved safety."

For an analyst ratings summary and ratings history on Agomab Therapeutics click here. For more ratings news on Agomab Therapeutics click here.

Shares of Agomab Therapeutics closed at $16.21 yesterday.

You May Also Be Interested In

• Trex (TREX) Reiterated at Hold by Benchmark as Partnership Agreement Announced
• Intuitive Surgical (ISRG) Reiterated at Buy by Stifel After Survey of 100 Robotic Surgeons
• Trex (TREX) PT Raised to $47 at Stifel on Raised Estimates